Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
MNMD Transcript
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call summary highlights strong financial health, promising Phase III trials, and significant market opportunities for MM120 ODT. The Q&A section reveals enthusiasm from KOLs and psychiatrists, and no major negative concerns were raised. While some management responses were unclear, overall sentiment remains positive, particularly with strategic commercial readiness and financial stability. Adjustments for potential positive catalysts, like new partnerships or optimistic guidance, were not applicable. Given the company's robust position, a positive stock price movement (2% to 8%) is expected over the next two weeks.
Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript
Unknown7-31
The earnings call summary indicates a mixed outlook. Financial health is stable, with a cash runway until 2027, but R&D expenses will increase. The MM120 program shows promise with breakthrough therapy designation, but no immediate revenue impact is expected. The Q&A reveals cautious optimism but lacks specific enrollment and reimbursement details. Given the absence of immediate catalysts and the potential for increased expenses, the stock price is likely to remain neutral over the next two weeks.
MindMed at RBC Conference: Progress in Psychedelic Therapies
Neutral5-21
MNMD Slides
MNMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.